Cancer Genetics and Epigenetics 2024, Vol.12, No.4, 223-233 http://medscipublisher.com/index.php/cge 230 clearance rates (Corrò et al., 2017). Additionally, sensitive methods such as endonuclease scanning and Sanger sequencing have been employed to detect VHL mutations and promoter hypermethylation, achieving a high mutation detection rate of 82.4% in clear cell renal cell carcinoma (ccRCC) cases (Nickerson et al., 2008). These advancements suggest that further refinement and combination of these technologies could enhance the detection and analysis of VHL mutations, potentially leading to earlier and more accurate diagnosis of RCC. Liquid biopsy techniques, which involve the analysis of circulating tumor DNA (ctDNA) in blood samples, offer a non-invasive alternative for cancer diagnosis and monitoring. However, the application of liquid biopsy in RCC diagnosis faces challenges due to the low levels of ctDNA released by renal tumors. A study investigating the clinical applicability of ctDNA as a liquid biopsy in RCC found that while specific VHL mutations could be detected in ctDNA from RCC xenografts, the detection in patient samples was limited (Corrò et al., 2017). This highlights the need for highly sensitive detection methods and prior knowledge of the specific mutations. Despite these challenges, the potential of liquid biopsy techniques in RCC diagnosis remains promising, and further research is needed to improve their sensitivity and reliability. 6.2 Integration of multi-omics approaches The integration of multi-omics approaches, including genomics, transcriptomics, and proteomics, provides a comprehensive understanding of the molecular mechanisms underlying RCC. For example, needle core biopsies have been shown to provide ample material for genomic and proteomic studies, allowing for the extraction of high-quality DNA, RNA, and protein (Kurban et al., 2012). This enables the simultaneous analysis of genetic mutations, gene expression profiles, and protein alterations, offering a holistic view of the tumor biology. By combining these data, researchers can identify key molecular pathways involved in RCC development and progression, leading to the discovery of novel biomarkers and therapeutic targets. The integration of multi-omics approaches has the potential to significantly enhance the accuracy of VHL-based diagnostics. For instance, a comprehensive analysis of VHL gene alterations, including mutations and promoter hypermethylation, revealed that 91% of ccRCCs exhibited genetic or epigenetic alterations of the VHL gene (Nickerson et al., 2008). This high prevalence underscores the importance of VHL alterations in RCC and suggests that incorporating multi-omics data could improve diagnostic accuracy. Additionally, the use of comparative genomic hybridization (CGH) on fine needle aspiration biopsies has been shown to improve the differential diagnosis of renal tumors, further supporting the utility of multi-omics approaches in enhancing VHL-based diagnostics (Vieira et al., 2010). 6.3 Development of targeted therapies The development of targeted therapies based on VHL mutation status holds great promise for improving RCC treatment outcomes. VHL gene alterations are a hallmark of ccRCC, and understanding the specific mutations can guide the development of targeted therapies. For example, the identification of novel VHL mutations and mutation hotspots provides valuable insights into the molecular mechanisms driving RCC, which can be exploited for therapeutic intervention (Brauch et al., 2000; Banks et al., 2006). Future research should focus on identifying and validating new therapeutic targets associated with VHL mutations, as well as developing drugs that specifically target these alterations. Resistance to current treatments remains a significant challenge in RCC management. Research into new therapeutic targets and strategies is essential for overcoming this resistance. Studies have shown that VHL alterations are associated with advanced tumor stages and specific mutation hotspots, suggesting that targeting these alterations could be an effective strategy (Brauch et al., 2000). Additionally, the exploration of epigenetic changes, such as promoter hypermethylation, offers another avenue for therapeutic intervention (Banks et al., 2006; Nickerson et al., 2008). By combining targeted therapies with strategies to modulate epigenetic changes, it may be possible to overcome resistance and improve treatment efficacy in RCC patients. In conclusion, the future prospects and research directions in the application of VHL gene in kidney cancer diagnosis are promising. Advances in diagnostic technologies, the integration of multi-omics approaches, and the
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==